◆ NeutralTOVX
Theriva™ Biologics anuncia una agrupación de acciones
GlobeNewswire Inc.·
Theriva Biologics (NYSE American: TOVX) announced a 1-for-30 reverse stock split effective December 1, 2026, to comply with NYSE price per share requirements. The split will reduce outstanding shares from approximately 45.9 million to 1.5 million. The company is a clinical-stage biopharmaceutical firm developing oncolytic adenovirus therapies for cancer treatment, with VCN-01 as its lead candidate.
Read Full Article at GlobeNewswire Inc. →